Skin communicates what we deeply feel: antibiotic prophylactic treatment to reduce epidermal growth factor receptor inhibitors induced rash in lung cancer (the Pan Canadian rash trial)

Affiliations

¹ Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico ;
² Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico; ; Comprehensive Cancer Center, Medica Sur Clinic and Foundation, México City, México;
³ Department of Dermatology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico ;
⁴ Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogota, Colombia.

Editorial

Oscar Arrieta et al. Ann Transl Med. 2016 Aug.

. 2016 Aug;4(16):313.

doi: 10.21037/atm.2016.08.19.

¹ Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico ;
² Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico; ; Comprehensive Cancer Center, Medica Sur Clinic and Foundation, México City, México;
³ Department of Dermatology, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico ;
⁴ Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Bogota, Colombia.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest to declare.

Pan Canadian Rash Trial: A Randomized Phase III Trial Evaluating the Impact of a Prophylactic Skin Treatment Regimen on Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Induced Skin Toxicities in Patients With Metastatic Lung Cancer.
Melosky B, Anderson H, Burkes RL, Chu Q, Hao D, Ho V, Ho C, Lam W, Lee CW, Leighl NB, Murray N, Sun S, Winston R, Laskin JJ. Melosky B, et al. J Clin Oncol. 2016 Mar 10;34(8):810-5. doi: 10.1200/JCO.2015.62.3918. Epub 2015 Nov 16. J Clin Oncol. 2016. PMID: 26573073 Clinical Trial.

1. Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007;56:317-26. 10.1016/j.jaad.2006.09.005 - DOI - PubMed
1. Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008;13:1201-4. 10.1634/theoncologist.2008-0149 - DOI - PubMed
1. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425-33. 10.1093/annonc/mdi279 - DOI - PubMed
1. Hammond-Thelin LA. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin 2008;26:121-59, ix. 10.1016/j.det.2007.08.010 - DOI - PubMed
1. Zaiss DM, van Loosdregt J, Gorlani A, et al. Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor. Immunity 2013;38:275-84. 10.1016/j.immuni.2012.09.023 - DOI - PMC - PubMed